← Leaderboards
Charles David James
Mayo Clinic Coll Of Medicine, Rochester
$11,072,867
Attributed
$13,439,380
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,439,380 · 13
By mechanism
R01$8,281,102 · 6
P50$3,745,002 · 4
P30$988,401 · 1
R21$424,875 · 1
P01$0 · 1
Top collaborators
- Claudia Katharina Petritsch5 shared
- Todd A Waldman5 shared
- Leonidas C Platanias4 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Donna R Session$603,204
- Pinku Mukherjee$4,770,733
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseIn VivoMouse ModelMalignant NeoplasmsResearch PersonnelMolecularXenograft ProcedureBaseGrantInvestigationBrain NeoplasmsChemotherapyClinical TrialsInterestAnimalsCellsOperative Surgical ProceduresGrowthIn VitroCell LineTranslational ResearchApoptoticSubcutaneous
Grant awards (62)
Developmental Therapeutics Core Shared Resource$113,221
P30 · FY2024 · CA · contact PI
Developmental Therapeutics Core Shared Resource$113,221
P30 · FY2023 · CA · contact PI
SLFN5: A Novel Therapeutic Target for Glioblastoma$345,625
R01 · FY2022 · NS
Developmental Therapeutics Core Shared Resource$147,006
P30 · FY2022 · CA · contact PI
Career Enhancement Program$78,509
P50 · FY2022 · CA · contact PI
SLFN5: A Novel Therapeutic Target for Glioblastoma$345,625
R01 · FY2021 · NS
Developmental Therapeutics Core Shared Resource$147,006
P30 · FY2021 · CA · contact PI
Career Enhancement Program$97,114
P50 · FY2021 · CA · contact PI
SLFN5: A Novel Therapeutic Target for Glioblastoma$345,625
R01 · FY2020 · NS
Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM$270,375
R01 · FY2020 · NS · contact PI
Developmental Therapeutics Core Shared Resource$147,006
P30 · FY2020 · CA · contact PI
Career Enhancement Program$92,689
P50 · FY2020 · CA · contact PI
SLFN5: A Novel Therapeutic Target for Glioblastoma$345,625
R01 · FY2019 · NS
Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM$337,969
R01 · FY2019 · NS · contact PI
Developmental Therapeutics Core Shared Resource$147,006
P30 · FY2019 · CA · contact PI
Career Enhancement Program$90,737
P50 · FY2019 · CA · contact PI
Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM$337,969
R01 · FY2018 · NS · contact PI
Career Enhancement Program$255,555
P50 · FY2018 · CA · contact PI
Developmental Therapeutics Core Shared Resource$149,926
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Core Shared Resource$8,622
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Core Shared Resource$8,489
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Core Shared Resource$6,898
P30 · FY2018 · CA · contact PI
Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM$337,969
R01 · FY2017 · NS · contact PI
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES$272,244
P50 · FY2017 · CA · contact PI
PRE-CLINICAL ANIMAL CORE$183,794
P50 · FY2017 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$356,473
R01 · FY2016 · NS · contact PI
Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM$337,969
R01 · FY2016 · NS · contact PI
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme$321,625
R01 · FY2016 · CA
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES$233,456
P50 · FY2016 · CA · contact PI
PRE-CLINICAL ANIMAL CORE$157,610
P50 · FY2016 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$356,473
R01 · FY2015 · NS · contact PI
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme$321,625
R01 · FY2015 · CA
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES$251,360
P50 · FY2015 · CA · contact PI
PRE-CLINICAL ANIMAL CORE$169,693
P50 · FY2015 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$351,981
R01 · FY2014 · NS · contact PI
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme$311,977
R01 · FY2014 · CA
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES$240,441
P50 · FY2014 · CA · contact PI
PRE-CLINICAL ANIMAL CORE$162,321
P50 · FY2014 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$341,104
R01 · FY2013 · NS · contact PI
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme$302,246
R01 · FY2013 · CA
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES$271,490
P50 · FY2013 · CA · contact PI
PRE-CLINICAL ANIMAL CORE$164,864
P50 · FY2013 · CA · contact PI
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy$352,165
R01 · FY2012 · NS · contact PI
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme$334,857
R01 · FY2012 · CA
EGRF Targeting of Therapeutic Liposomes for Treating Gliobastoma$193,125
R21 · FY2010 · NS · contact PI
EGRF Targeting of Therapeutic Liposomes for Treating Gliobastoma$231,750
R21 · FY2009 · NS · contact PI
Xenograft Model for Studying Amplified EGFR in GBM$304,644
R01 · FY2008 · NS · contact PI
Core--Xenograft Facility$253,765
P50 · FY2008 · CA · contact PI
Xenograft Model for Studying Amplified EGFR in GBM$303,657
R01 · FY2007 · NS · contact PI
Core--Xenograft Facility$277,074
P50 · FY2007 · CA · contact PI
Xenograft Model for Studying Amplified EGFR in GBM$282,529
R01 · FY2006 · NS · contact PI
Core--Xenograft Facility$160,331
P50 · FY2006 · CA · contact PI
Xenograft Model for Studying Amplified EGFR in GBM$289,327
R01 · FY2005 · NS
Core--Xenograft Facility$168,386
P50 · FY2005 · CA
Xenograft Model for Studying Amplified EGFR in GBM$301,202
R01 · FY2004 · NS
Core--Xenograft Facility$163,569
P50 · FY2004 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$0
P01 · FY2002 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$0
P01 · FY2002 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$222,233
R01 · FY2001 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$0
P01 · FY2001 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$0
P01 · FY2001 · CA
EGFR MUTATIONS IN MALIGNANT GLIOMAS$222,233
R01 · FY2000 · CA